Solventum (NYSE:SOLV) Price Target Raised to $101.00

Solventum (NYSE:SOLV) had its price target upped by stock analysts at Wedbush from $94.00 to $101.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush’s price target indicates a potential upside of 19.53% from the company’s previous close.

A number of other research firms have also issued reports on SOLV. BMO Capital Markets initiated coverage on Solventum in a report on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 target price on the stock. Piper Sandler dropped their price objective on Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. BTIG Research lifted their target price on Solventum from $91.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday. Wells Fargo & Company decreased their price target on Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a report on Wednesday, May 6th. Finally, Weiss Ratings upgraded shares of Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, July 17th. Seven research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $90.45.

Solventum Price Performance

Shares of NYSE:SOLV traded down $2.98 during trading on Thursday, reaching $84.50. The company had a trading volume of 645,530 shares, compared to its average volume of 1,407,590. The company has a fifty day moving average of $79.09 and a two-hundred day moving average of $74.36. Solventum has a 12 month low of $62.38 and a 12 month high of $90.00. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96. The stock has a market capitalization of $14.63 billion, a P/E ratio of 10.36, a price-to-earnings-growth ratio of 1.36 and a beta of 0.60.

Solventum (NYSE:SOLV) last released its earnings results on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.64. The firm had revenue of $2.21 billion for the quarter, compared to analysts’ expectations of $2.15 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The company’s quarterly revenue was up 2.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.69 earnings per share. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Equities research analysts forecast that Solventum will post 6.58 earnings per share for the current year.

Hedge Funds Weigh In On Solventum

A number of large investors have recently added to or reduced their stakes in SOLV. Assetmark Inc. raised its position in Solventum by 21.4% during the 4th quarter. Assetmark Inc. now owns 725 shares of the company’s stock valued at $57,000 after purchasing an additional 128 shares during the last quarter. BOKF NA boosted its stake in shares of Solventum by 6.9% during the third quarter. BOKF NA now owns 2,193 shares of the company’s stock worth $160,000 after buying an additional 141 shares during the period. Smartleaf Asset Management LLC grew its holdings in Solventum by 23.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 744 shares of the company’s stock valued at $60,000 after buying an additional 142 shares during the period. NewEdge Advisors LLC increased its stake in Solventum by 2.2% during the first quarter. NewEdge Advisors LLC now owns 6,707 shares of the company’s stock valued at $438,000 after purchasing an additional 144 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators boosted its holdings in shares of Solventum by 39.5% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 516 shares of the company’s stock worth $41,000 after buying an additional 146 shares during the period.

Solventum News Roundup

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Quarterly earnings and revenue exceeded expectations. Solventum reported second-quarter adjusted EPS of $2.55, well above the $1.91 consensus and up from $1.69 a year earlier. Revenue reached $2.21 billion versus estimates of $2.15 billion, while organic sales increased 9.5%. Solventum Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management raised its 2026 outlook. Solventum increased full-year adjusted EPS guidance to $7.10-$7.20, above the approximately $6.55 analyst consensus, and also raised its expectations for organic sales growth and free cash flow. Solventum Raises 2026 EPS Guidance
• Positive Sentiment: Analyst sentiment improved. Stifel Nicolaus raised its price target from $90 to $100 and upgraded Solventum to “buy,” implying approximately 18.9% potential upside from the cited price. This supports the view that the earnings beat and higher guidance could improve the company’s valuation. Benzinga Analyst Update
• Neutral Sentiment: Solventum plans to separate its Health Information Systems business. The company says the move will create a more focused MedTech company, allow the healthcare software business to pursue its own growth strategy and potentially unlock shareholder value. However, the separation will require execution and could create near-term uncertainty, particularly amid activist pressure to divest the business. Solventum to Separate Healthcare Software Business

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.